ReviewDrugs in context2018
Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus.
Review in Drugs in context, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Article
- From guidelines to practice: an Egyptian expert opinion on type 2 diabetes mellitus management in primary care settings.BMC primary care · 2025Article
- Risk of New-Onset Diabetes Mellitus Among Adults Using Statins: A Retrospective Cohort Study in Thailand.Cureus · 2025Article
- Systemic evaluation of inclisiran on the risk of new-onset diabetes and hyperglycemia compared to evolocumab and atorvastatin.Frontiers in pharmacology · 2025Article
- AI-based integration of ECG biomarkers for assessing cardiac risk in type 2 diabetes mellitus with comorbid conditions for patient stratification.Frontiers in medicine · 2025Article
- Effects of ACLY Inhibition on Body Weight Distribution: A Drug Target Mendelian Randomization Study.Genes · 2024Article
- Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature.Drugs · 2024Review
- Cornuside inhibits glucose-induced proliferation and inflammatory response of mesangial cells.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2023Article
- Article
- Genetics, Safety, Cost-Effectiveness, and Accessibility of Injectable Lipid-Lowering Agents: A Narrative Review.Journal of lipids · 2023Review
- Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond.International journal of molecular sciences · 2022Review
- The role of non-HDL cholesterol and atherogenic indices in predicting poor glycemic control among type 2 diabetic patients in Basrah, Iraq.Qatar medical journal · 2022Article
- Relationship between Lipid Profiles and Glycemic Control Among Patients with Type 2 Diabetes in Qingdao, China.International journal of environmental research and public health · 2020Article
- Safety and Tolerability of PCSK9 Inhibitors: Current Insights.Clinical pharmacology : advances and applications · 2020Review
- Current perspectives on the use of statins in the treatment of dyslipidaemic patients: focus on pitavastatin.Drugs in context · 2020Article
- Evaluation of glycemic status among hypercholesterolemic patients on atorvastatin in a tertiary care hospital - A retrospective study.Indian journal of pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipid-lowering therapy is used very commonly nowadays not only for the optimization of the lipid profile but also to reduce cardiovascular risk. However, some studies have linked the use of certain lipid-lowering agents with an increased risk for impaired glycemic control and new-onset diabetes mellitus, a condition well established as an important risk factor for cardiovascular disease. On the other hand, some other lipid-lowering agents have been shown to have a beneficial effect on glucose metabolism. Profound knowledge of these differences would enable the clinician to choose the right lipid-lowering medication for each individual patient, so that the benefits would outweigh the risk of side effects. This review aims to present and discuss the clinical and scientific data pertaining to the impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.